PIK3CA and breast carcinoma: These results led to the clearance of this drug for the treatment of patients with HR+/HER2− PIK3CA-mutated advanced breast cancer by both the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) [15].